• English
  • Français
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Portrait
  • Continuing Education
  • Contact Us
  • Subscribe
Home > Archives for SGLT2

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

August 25, 2020 PharmacoEpidemiology

Diabetes Care Aug 2020, dc200267; DOI: 10.2337/dc20-0267 Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, MichaelFralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E.Ronksley, Kristian B. Filion, Pierre Ernst, Lisa M. Lix for the Canadian Network for Observational Drug Effect Studies (CNODES) … [Read more...]

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

September 23, 2020 PharmacoEpidemiology

BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa, on behalf of the Canadian Network for Observational Drug … [Read more...]

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

July 28, 2020 PharmacoEpidemiology

Annals of Internal Medicine 2020 July 28. DOI: 10.7326/M20-0289 Antonios Douros, MD, PhD; Lisa M. Lix, PhD; Michael Fralick, MD, PhD; Sophie Dell’Aniello, MSc; Baiju R. Shah, MD, PhD; Paul E. Ronksley, PhD; Eric Tremblay, BPharm, MSc; Nianping Hu, PhD; Silvia Alessi-Severini, PhD; Anat Fisher, MD, PhD; Shawn C. Bugden, PharmD, MSc; Pierre Ernst, MD, MSc; and Kristian B. Filion, PhD; for the … [Read more...]

Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study

May 13, 2020 PharmacoEpidemiology

First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]

Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

April 30, 2020 PharmacoEpidemiology

BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]

  • About Us
    • Oversight Committee
    • Questions & Answers
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
  • Portrait
    • Frequently Asked Questions
    • Portrait Contact
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
    • Best Evidence
  • Contact Us
  • Terms & Policies
    • Legal Information & Terms of Use
    • Privacy Policy
    • Acceptable Use Policy

Categories

  • News (123)
  • Therapeutics Letter (133)
  • Portrait (1)
  • Drug Assessments (39)
  • PharmacoEpidemiology (75)
  • Podcasts & Videos (56)

Recent Seminars

[Apr 14] Therapeutics Initiative Best Evidence Webinar: Optimising Outcomes in Persons with Carotid Stenosis: Where are we up to in April 2021?

Register
Share

[Apr 28] TI Methods Speaker Series: The PRISMA 2020 Statement

Register
Share

Methods Speaker Series 2021

Share

Therapeutics Initiative

Our mission is to provide physicians, nurse practitioners, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3
Contact us
Office: +1 604-822-0700
Fax: +1 604-822-0701

UBC logoISDB logo

Subscribe

Subscribe to receive email notifications from the TI about the Therapeutics Letter, upcoming educational events, personal prescribing portraits and other news and recent publications. SUBSCRIBE

© 1994 - 2021 Therapeutics Initiative · Terms & Policies · TM